Introduction: Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor prescribed
as part of first-line highly active antiretroviral therapy (HAART) in South Africa. Despite …

Objectives Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa.
However, exposure to efavirenz shows marked interindividual variability that is genetically …

Efavirenz is mainly metabolized by cytochrome P450 2B6 (CYP2B6). This study aimed to
examine the frequencies of CYP2B6 and the association between CYP2B6 polymorphisms …

Aims Genetic factors, notably CYP2B6 516G→ T [rs3745274] and 983T→ C [rs28399499],
explain much of the interindividual variability in efavirenz pharmacokinetics, but data from …

Importance of the field: The use of the first generation non-nucleoside reverse transcriptase
inhibitor efavirenz (EFV) as a component of first-line antiretroviral therapy has been …

Abstract Papua New Guinea (PNG) has a high HIV/AIDS prevalence and very high
frequency of the CYP2B6 c. 516G> T (rs3745274) variant. We have conducted the first …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Cytochrome P450 (CYP) 2B6
polymorphisms, particularly c. 516G→ T, are strongly associated with plasma efavirenz …

Methods HIV/AIDS patients were recruited from Themba Lethu Clinic, at Helen Joseph
Hospital, Johannesburg. Blood samples for plasma drug levels and DNA extraction were …

Inter-individual variability in efavirenz (EFV) pharmacokinetics and dynamics is dominantly
driven by the polymorphism in cytochrome P450 (CYP) isoenzyme 2B6 516G> T. We …

Abstract Background The 516G> T polymorphism in exon 4 of the CYP2B6 gene has been
associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations …